Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 10/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GNRHR | P30968 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27213468 | 0.92 | ALPL (0.33) | CASRNR1I2ALDH1A1KMT2AGNRHR | |
| SCHEMBL25760181 | 0.90 | LTB4R (0.32) | ALDH1A1KMT2AGNRHRPKM | |
| SCHEMBL20543671 | 0.89 | GNRHR (0.34) | CASRNR1I2ALDH1A1KMT2AGNRHR | |
| SCHEMBL25760191 | 0.89 | CASR (0.36) | CASRNR1I2KMT2AGNRHRPARP1 | |
| SCHEMBL30110624 | 0.89 | GNRHR (0.34) | CASRNR1I2ALDH1A1KMT2AGNRHR | |
| SCHEMBL21751334 | 0.89 | GNRHR (0.32) | CASRALDH1A1KMT2AGNRHR | |
| SCHEMBL21751404 | 0.87 | CASR (0.35) | CASRNR1I2ALDH1A1KMT2AGNRHR | |
| SCHEMBL21751403 | 0.86 | ALDH1A1 (0.34) | ALDH1A1KMT2AGNRHR | |
| SCHEMBL19206668 | 0.84 | NPY5R (0.38) | ALDH1A1KMT2APKM | |
| SCHEMBL30110484 | 0.83 | GNRHR (0.34) | CASRKMT2AGNRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691976-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691976-B2 | Coelenterazine analogues | GLB1, SI, TCF7L2 | CASR 2864/4885NR1I2 2578/4885ALDH1A1 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.